Document:

Exhibit 4.2

 

THE SECURITIES REPRESENTED
HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY BE OFFERED, SOLD, ASSIGNED, PLEDGED,
HYPOTHECATED, TRANSFERRED OR OTHERWISE DISPOSED OF (EACH, A “TRANSFER”) ONLY IF SUCH SECURITIES ARE REGISTERED UNDER
THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR IF SUCH TRANSFER IS MADE PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT AND SUCH STATE SECURITIES LAWS AFTER PROVIDING AN OPINION OF COUNSEL TO SUCH EFFECT.

 

THE SECURITIES REPRESENTED
HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AS SET FORTH
IN A SECURITIES PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED
AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

COMMON STOCK PURCHASE WARRANT

 

SORRENTO
THERAPEUTICS, INC.

 

Warrant Shares: ___________ Initial Issuance
Date: June 13, 2018

 

THIS COMMON STOCK PURCHASE
WARRANT (this “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and
from time to time on or after December 11, 2018 (the “Initial Exercise Date”) and on or prior
to the close of business on December 13, 2023 (the “Termination Date”) but not thereafter, to
subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”),
up to ___________shares of Common Stock (subject to the limitation in Section 2(e) and as subject to adjustment hereunder,
the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal
to the Exercise Price (as defined below).

 

Section 1.Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(as may be amended or restated from time to time, the “Purchase Agreement”), dated March 26, 2018, by
and among the Company and the purchasers identified on Schedule A thereto.
For purposes of this Warrant, the following capitalized terms have the meanings assigned to them in this Section 1.

 

a)                 
“Business Day” means any day except a Saturday, a Sunday or any other day on which commercial
banks are required or authorized to close in the City of New York, State of New York or the City of San Diego, State of California.

 

    1 

     

    

  

b)                 
“Change of Control” means the occurrence of any of the following events: (i) any “person”
(as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in
Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting
power represented by the Company’s then-outstanding voting securities, except that any change in the beneficial ownership
of the securities of the Company as a result of a private financing of the Company that is approved by the Company’s board
of directors, shall not be deemed to be a Change of Control; (ii) the consummation of the sale, lease, license or disposition by
the Company of all or substantially all of the Company’s assets; or (iii) the consummation of a merger or consolidation of
the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
voting securities of the surviving entity or its parent) at least 50% of the total voting power represented by the voting securities
of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

  

c)                 
“Closing Bid Price” means, for any date, the price determined by the first of the following clauses
that applies: (i) if the Common Stock is then listed or quoted on a Trading Market, the last reported closing bid price for such
date on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P., (ii) if the Common
Stock is not then listed on a Trading Market or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock
are then reported in the “Pink Sheets” published by OTC Markets Group Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the last bid price per share of the Common Stock so reported, or (iii) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.

 

d)                 
“Trading Day” means a day on which the Common Stock
is traded on a Trading Market or, if the Common Stock is not traded on a Trading Market, then on the principal securities exchange
or securities market on which the Common Stock is then traded.

 

e)                 
“Trading Market” means any market or exchange of The Nasdaq
Stock Market LLC or the New York Stock Exchange.

 

f)                  
“VWAP” means, for any date, the price determined by the first of the following clauses that applies:
(i) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported
by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if
the Common Stock is not then listed on a Trading Market or quoted for trading on the OTC Bulletin Board and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (iii) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.

 

    2 

     

    

  

Section 2.Exercise.

 

a)                 
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the principal office of the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Company) of a duly executed facsimile or original copy of the Notice of Exercise Form annexed hereto
(each, a “Notice of Exercise”). Unless being exercised on a cashless basis in accordance with Section
2(c), within three Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United
States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three Trading Days of the
date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall inform the Holder
if a Notice of Exercise has not been duly completed within one Business Day of receipt of such notice, but shall not refuse or
object to the issuance of the Warrant Shares upon receipt of, and pursuant to, a duly completed Notice of Exercise. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

b)                 
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $8.77, subject
to adjustment hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. If at the time of exercise of this Warrant there is no effective registration statement registering
the resale of the Warrant Shares by the Holder, the Holder, at its option, may exercise this Warrant, in whole or in part, by means
of a “cashless exercise” in which the Holder shall be entitled to receive a certificate for the number of Warrant Shares
equal to the quotient obtained by dividing [(Y)*(A-B)] by (A), where:

 

(A)
= the average of the Closing Bid Price of the shares of Common Stock for the five consecutive Trading Days ending on the last Trading
Day immediately preceding the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,”
as set forth in the applicable Notice of Exercise;

 

    3 

     

    

  

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(Y)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

d)                 
Mechanics of Exercise.

 

i.                       
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company’s
transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s prime
broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system and there is an effective registration statement permitting the issuance of
the Warrant Shares to or resale of the Warrant Shares by the Holder, or otherwise by physical delivery to the address specified
by the Holder in the Notice of Exercise by the date that is three Trading Days after the latest of (A) the delivery to the Company
of the Notice of Exercise, (B) surrender of this Warrant (if required), and (C) payment of the aggregate Exercise Price as set
forth above, including by means of a “cashless exercise” (such date, the “Warrant Share Delivery Date”).
The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as of the date this Warrant has been exercised, with
payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(v)
prior to the issuance of such shares, having been paid. 

 

ii.                       
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of the Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing
the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant
Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.                       
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the
certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder
will have the right to rescind such exercise. Any rescission by the Holder pursuant to this Section 2(d)(iii) shall not
affect any other remedies available to the Holder under Laws or equity as a result of the Company’s failure to timely deliver
the Warrant Shares.

 

    4 

     

    

  

iv.                       
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

v.                       
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder
for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and
expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder, and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto.

 

vi.                       
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

e)                 
Limitation on Exercise. The Company shall not effect any exercise of this Warrant, and the Holder shall not have
the right to exercise any portion of this Warrant, to the extent that after giving effect to such issuance after exercise as set
forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder’s Affiliates) would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the
limitation contained in this Section 2(e), applies, the determination of whether this Warrant is exercisable and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
shall be deemed to be the Holder’s determination of whether this Warrant is exercisable and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder
will be deemed to represent to the Company each time it delivers a Notice of Exercise that such Notice of Exercise has not violated
the restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e),
in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as stated in the most recent of the following: (i) the Company’s most recent periodic or annual report filed with the
Securities and Exchange Commission, as the case may be, (ii) a more recent public announcement by the Company, or (iii) a more
recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding.
Upon the written request of the Holder, the Company shall within two business days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company by the Holder or its Affiliates since the date as
of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall
be 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the applicable issuance of shares
of Common Stock pursuant to this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section 2(e). Any increase or decrease in the Beneficial
Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The Beneficial Ownership
Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.

 

    5 

     

    

  

Section 3.Certain
Adjustments.

 

a)                 
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

b)                 
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders
of Common Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or
warrants to subscribe for or purchase any security, then in each such case the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such
distribution by a fraction of which the numerator shall be such VWAP on such record date less the then per share fair market value
at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share
of Common Stock as determined by the Board of Directors of the Company in good faith, and of which the denominator shall be the
VWAP determined as of the record date mentioned above. In either case the adjustments shall be described in a statement provided
to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one
share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately
after the record date mentioned above.

 

c)                 
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued
and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any)
issued and outstanding.

 

    6 

     

    

  

d)                 
Notice to the Holder.

 

i.     
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
3, the Company shall, at the request of the Holder, promptly compute such adjustment, in good faith, in accordance with the
terms of this Warrant, and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise
Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable)
and setting forth a brief statement of the facts requiring such adjustment. Upon written request, the Company will promptly deliver
a copy of each such certificate to the Holder.

 

ii.     
Notice to Allow Exercise by the Holder. If (A) the Company shall declare a dividend (or any other distribution in
whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the
Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock or rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights of the Company, (D) a Change of Control is pending, or
(E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant
Register (as defined below) of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distribution, redemption, rights or warrants are to be determined, or (y) the date on which such Change of Control
is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such Change of Control;
provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity
of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein. Except as otherwise prohibited by applicable laws, to the extent that any notice provided pursuant
to this Section 3(d)(ii) contains material, non-public information regarding the Company, the Company shall, disclose such
information regarding the Company in a Current Report on Form 8-K and file such Current Report on Form 8-K with the SEC no later
than the second Trading Day following the date such notice is delivered to the Holder.

 

    7 

     

    

  

Section 4.Transfer
of Warrant.

 

a)                 
Transferability. Subject to applicable securities laws, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Warrant Shares without having a new Warrant issued.

 

b)                 
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant
or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)                 
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company
may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

    8 

     

    

  

Section 5.Warrant
Agent. The Company shall serve as warrant agent under this Warrant. Upon 15 days’ notice to the Holder, the Company may
appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting
from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or
any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession
as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as it shall
appear upon the Warrant Register.

 

Section 6.Miscellaneous.

 

a)                 
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)                 
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of this Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

c)                 
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

    9 

     

    

  

d)                 
Authorized Shares.

 

The Company
covenants that, during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this
Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon
the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to
assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any
requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue).

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of the Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e)                 
Governing Law. This Warrant shall be construed under the laws of the State of California, without regard to principles
of conflicts of law or choice of law that would permit or require the application of the laws of another jurisdiction. All actions
or proceedings arising directly or indirectly from or in connection this Warrant shall be resolved in accordance with Section 10
of the Purchase Agreement, as may be amended or restated from time to time.

 

    10 

     

    

  

f)                  
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant constitute
“restricted securities” within the meaning of Rule 144 under the Securities Act and may not be sold, pledged or otherwise
disposed of unless they are subsequently registered under the Securities Act and applicable state securities laws or unless an
exemption from registration thereunder is available.

 

g)                 
Fees and Expenses. Except as otherwise provided in this Warrant, all expenses incurred in connection with this Warrant
and the transactions contemplated hereby shall be paid by the party incurring such expenses.

 

h)                 
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Warrant shall be given in accordance with Section 16 of the Purchase Agreement, as may be amended or restated from time
to time.

 

i)                  
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

j)                  
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)                 
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of the Holder from time
to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)                  
Amendment. No provision of this Warrant may be amended, waived or modified other than by an instrument in writing
signed by the Company and the Holder.

 

m)              
Severability. If any provision of this Warrant shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the remainder of this Warrant in that jurisdiction or the
validity or enforceability of any provision of this Warrant in any other jurisdiction.

 

n)                 
Headings. The headings of this Warrant are for convenience of reference and shall not form part of, or effect the
interpretation of, this Warrant.

 

o)                 
Language; Currency. This Warrant has been prepared in the English language and the English language shall control
its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or
other communications between the parties regarding this Warrant, shall be in the English language. All references to “$”
contained in this Warrant shall refer to United States Dollars unless otherwise stated.

 

********************

 

(Signature Page Follows)

 

    11 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	SORRENTO THERAPEUTICS, INC. 
	 	 	 	 
	 	By:	 
	 	 	Name: 	Henry Ji, Ph.D. 
	 	 	Title: 	President and Chief Executive Officer  

  

 

 

 

 

[Signature Page to Common Stock Purchase
Warrant]

     

     

    

 

NOTICE OF EXERCISE

 

To:SORRENTO
THERAPEUTICS, inc.

 

(1)              
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Common
Stock Purchase Warrant (the “Warrant”), and tenders herewith payment of the applicable exercise price,
together with all applicable transfer taxes, if any.

 

(2)              
Payment shall take the form of (check applicable box):

 

[ ] in lawful
money of the United States; or

 

[ ] if permitted,
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 2(c) of
the Warrant, to exercise the Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in Section 2(c) of the Warrant.

 

(3)              
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other
name as is specified below:

 

_______________________________

 

The Warrant Shares shall be delivered to
the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: ______________________________________________________

Signature of Authorized Signatory of
Investing Entity: ________________________________

Name of Authorized Signatory: __________________________________________________

Title of Authorized Signatory: ___________________________________________________

Date: ______________________________________________________________________

 

 

 

     

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED,
all of or [_______] of the shares of the foregoing Common Stock Purchase Warrant (the “Warrant”) and
all rights evidenced thereby are hereby assigned to

 

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

 

 

_______________________________________________________________

 

Dated: ______________,
_______

 

 

Holder’s Signature:_____________________________

 

Holder’s Address:_____________________________

 

_____________________________

 

 

 

Signature Guaranteed: ___________________________________________

 

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the Warrant.Exhibit 4.3

 

 

SORRENTO THERAPEUTICS, INC.

 

REGISTRATION RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made as of June 13, 2018, by and among
Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on
Schedule A hereto (each, a “Purchaser” and collectively,
the “Purchasers”) and such other Persons, if any, from time to time, that become a party hereto as holders
of Registrable Securities (as defined below). Unless otherwise defined herein, capitalized terms used in this Agreement have the
meanings ascribed to them in that certain Securities Purchase Agreement dated as of March 26, 2018 by and among the Company and
the Purchasers (as may be amended or restated from time to time, the “Purchase Agreement”).

 

RECITALS

 

Whereas,
pursuant to the Purchase Agreement, concurrently with the execution of this Agreement, at the Closing, each Purchaser will purchase
from the Company, and the Company will issue and sell to each Purchaser, (i) a convertible promissory note in the form attached
as Exhibit A to the Purchase Agreement,
in the aggregate principal amount set forth opposite such Purchaser’s name on Schedule
A hereto (each, a “Note” and collectively, the “Notes”), and (ii)
a warrant to purchase such number of shares of Common Stock as is set forth opposite such Purchaser’s name on Schedule
A hereto (each, a “Warrant” and collectively, the “Warrants”);

 

Whereas,
the Notes will be convertible into shares of Common Stock from time to time, and the Warrants will be exercisable into shares of
Common Stock from time to time on the date that is 181 days after the Closing Date, in each case in accordance with the terms thereof;
and

 

Whereas,
in connection with the execution and delivery of the Purchase Agreement and the consummation of the transactions contemplated thereby,
the Company has agreed to grant the Holders (as defined below) certain registration rights as set forth below.

 

Now,
Therefore, in consideration of the mutual promises and covenants herein contained, and other consideration, the receipt
and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

 

Article
I.

Definitions

 

1.1       Definitions.
As used in this Agreement, the following terms shall have the meanings set forth below:

 

(a)       “Additional
Shares” means any shares of Common Stock issued to the Purchasers pursuant to a stock split, stock dividend or other
distribution with respect to, or in exchange or in replacement of, the Shares.

 

(b)       “Affiliate”
means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls, is controlled by,
or is under common control with such specified Person, including, without limitation, any general partner, limited partner, member,
officer, director or manager of such Person and any venture capital or private equity fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. For purposes of
this definition, the terms “controls,” “controlled by,” or “under
common control with” means the possession, direct or indirect, of power to direct or cause the direction of management
or policies (whether through ownership of voting securities, by contract or otherwise).

 

     

     

    

 

(c)       “Business
Day” means a weekday on which banks are open for general banking business in San Diego, California.

 

(d)       
“Common Stock” means shares of the common stock of the Company, par value $0.0001 per share.

 

(e)       “Entity”
means any corporation (including any non profit corporation), general partnership, limited partnership, limited liability partnership,
joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise,
association, organization or entity.

 

(f)       “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder,
as the same may be amended from time to time.

 

(g)       “Governmental
Body” means any domestic or foreign multinational, federal, state, provincial, municipal or local government (or
any political subdivision thereof) or any domestic or foreign governmental, regulatory or administrative authority or any department,
commission, board, agency, court, tribunal, judicial body or instrumentality thereof, or any other body exercising, or entitled
to exercise, any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power of any nature
(including any arbitral body).

 

(h)       “Holder”
(collectively, “Holders”) means any Purchaser and any transferee permitted under Section 3.1, in each
case, to the extent holding Registrable Securities.

 

(i)       “Person”
means any individual, Entity, trust, Governmental Body or other organization.

 

(j)       “register,”
“registered” and “registration” refer to a registration effected by filing
with the SEC a registration statement in compliance with the Securities Act, and the declaration or ordering by the SEC of the
effectiveness of such registration statement.

 

(k)       “Registrable
Securities” means (i) the Shares, and (ii) any Additional Shares; provided, however, that Shares or
Additional Shares shall cease to be treated as Registrable Securities on the earliest to occur of, (a) the date such security has
been disposed of pursuant to an effective registration statement, (b) the date on which such security is sold pursuant to Rule
144, (c) the date on which such security ceases to be outstanding, or (d) the date on which the Holder thereof, together with its
Affiliates, is able to dispose of all of its Registrable Securities without restriction or limitation pursuant to Rule 144 and
without the requirement to be in compliance with Rule 144 (or any successor rule).

 

    	 	2	 

     

    

 

(l)       “Registration
Expenses” means any and all expenses incident to the performance
of or compliance with this Agreement, including without limitation: (i) all registration and filing fees; (ii) all fees and expenses
associated with a required listing of the Registrable Securities on any securities exchange; (iii) fees and expenses with respect
to filings required to be made with an exchange or any securities industry self-regulatory body; (iv) fees and expenses of compliance
with securities or “blue sky” laws (including reasonable fees and disbursements of counsel for the underwriters or
holders of securities in connection with blue sky qualifications of the securities and determination of their eligibility for investment
under the laws of such jurisdictions); (v) printing, messenger, telephone and delivery expenses of the Company; (vi) fees and disbursements
of counsel for the Company and customary fees and expenses for independent certified public accountants retained by the Company
(including the expenses of any comfort letters, or costs associated with the delivery by independent certified public accountants
of a comfort letter or comfort letters, if such comfort letter or comfort letters is required by the managing underwriter); (vii)
securities acts liability insurance, if the Company so desires; (viii) all internal expenses of the Company (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties); (ix) the expense of
any annual audit; and (x) the fees and expenses of any Person, including special experts, retained by the Company; provided,
however that “Registration Expenses” shall not include underwriting fees, discounts or commissions
attributable to the sale of the Registrable Securities or any legal fees and expenses of counsel to the Holders.

 

(m)       “Rule
144” means Rule 144 under the Securities Act.

 

(n)       “SEC”
means the Securities and Exchange Commission.

 

(o)       “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as the same
may be amended from time to time.

 

(p)       “Shares”
means any and all shares of Common Stock issuable upon conversion of the Notes and exercise of the Warrants.

 

Article
II.

Registration Rights

 

2.1       Resale
Registration Statements. Within 45 days following the Closing
Date, the Company shall (a) file with the SEC, or (b) have filed with
the SEC, a resale registration statement (together with any New Registration Statement (as defined below), the “Resale
Registration Statement”) pursuant to Rule 415 under the Securities Act pursuant to which all of the Registrable Securities
shall be included (on the initial filing or by supplement or amendment thereto) to enable the public resale on a delayed or continuous
basis of the Registrable Securities by the Holders. The Company shall file the Resale Registration Statement on such form as the
Company may then utilize under the rules of the SEC and use its best efforts to have the Resale Registration Statement declared
effective under the Securities Act as soon as practicable, but in no event more than the earlier of: (A) 120 days following
the Closing Date, and (B) five trading days after the date the
Company receives written notification from the SEC that the Resale Registration Statement will not be reviewed. The Company agrees
to use its best efforts to maintain the effectiveness of the Resale
Registration Statement, including by filing any necessary post-effective amendments and prospectus supplements, or, alternatively,
by filing one or more new registration statements (each, a “New Registration Statement”) relating to
the Registrable Securities as required by Rule 415 under the Securities Act, continuously until the date that is the earlier of
(i) four years following the date of effectiveness of the Resale Registration Statement, or (ii) the date on which the Holders
no longer hold any Registrable Securities covered by the Resale Registration Statement.

 

    	 	3	 

     

    

 

2.2       Provisions
Relating to Registration.

 

(a)       Notwithstanding
any other provisions of this Agreement to the contrary, the Company shall cause (i) the Resale Registration Statement (as of the
effective date of the Resale Registration Statement), any amendment thereof (as of the effective date thereof) or supplement thereto
(as of its date), (A) to comply in all material respects with the applicable requirements of the Securities Act and the rules and
regulations of the SEC, and (B) not to contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein not misleading, and (ii) any related prospectus, preliminary
prospectus and any amendment thereof or supplement thereto, as of its date, (A) to comply in all material respects with the applicable
requirements of the Securities Act and the rules and regulations of the SEC, and (B) not to contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided, however, the Company shall have
no such obligations or liabilities with respect to any written information pertaining to a Holder and furnished to the Company
by or on behalf of such Holder specifically for inclusion therein.

 

(b)       The
Company shall notify the Holders: (i) when the Resale Registration Statement or any amendment thereto has been filed with the SEC
and when the Resale Registration Statement or any post-effective amendment thereto has become effective; (ii) of any request by
the SEC for amendments or supplements to the Resale Registration Statement or the prospectus included therein or for additional
information; (iii) of the issuance by the SEC of any stop order suspending the effectiveness of the Resale Registration Statement
or the initiation of any proceedings for that purpose and of any other action, event or failure to act that would cause the Resale
Registration Statement not to remain effective; and (iv) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of any Registrable Securities for sale in any jurisdiction or the
initiation of any proceeding for such purpose.

 

(c)       As
promptly as practicable after becoming aware of such event, the Company shall notify the Holders of the happening of any event
(a “Suspension Event”), of which the Company has knowledge, as a result of which the prospectus included
in the Resale Registration Statement as then in effect, includes an untrue statement of a material fact or omission to state a
material fact required to be stated therein or necessary to make the statements therein not misleading, and use its best efforts
promptly to prepare a supplement or amendment to the Resale Registration Statement to correct such untrue statement or omission,
and deliver such number of copies of such supplement or amendment to the Holders as the Holders may reasonably request; provided,
however, that, for not more than 45 consecutive trading days (or a total of not more than 120 trading days in any 12 month
period), the Company may delay, to the extent permitted by and in a manner not in violation of applicable securities laws, the
disclosure of material non-public information concerning the Company (as well as prospectus or Resale Registration Statement updating),
the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company; provided,
further, that, if the Resale Registration Statement was not filed on Form S-3, such number of days shall not include the
15 calendar days following the filing of any Current Report on Form 8-K, Quarterly Report on Form 10-Q or Annual Report on Form
10-K, or other comparable form, for purposes of filing a post-effective amendment to the Resale Registration Statement.

 

    	 	4	 

     

    

 

(d)       Upon
a Suspension Event, the Company shall give written notice (a “Suspension Notice”) to the Holders to suspend
sales of the affected Registrable Securities, and such notice shall state that such suspension shall continue only for so long
as the Suspension Event or its effect is continuing and the Company is pursuing with reasonable diligence the completion of the
matter giving rise to the Suspension Event or otherwise taking all reasonable steps to terminate suspension of the effectiveness
or use of the Resale Registration Statement. In no event shall the Company, without the prior written consent of the Holders, disclose
to the Holders any of the facts or circumstances giving rise to the Suspension Event. The Holders shall not effect any sales of
the Registrable Securities pursuant to the Resale Registration Statement (or such filings), at any time after they have received
a Suspension Notice and prior to receipt of an End of Suspension Notice. The Holders may resume effecting sales of the Registrable
Securities under the Resale Registration Statement (or such filings), following further notice to such effect (an “End
of Suspension Notice”) from the Company. This End of Suspension Notice shall be given by the Company to the Holders
in the manner described above promptly following the conclusion of any Suspension Event and its effect. For the avoidance of doubt,
a Suspension Notice shall not affect or otherwise limit sales of affected Registrable Securities under Rule 144 or otherwise outside
of the Resale Registration Statement.

 

(e)       Notwithstanding
any provision herein to the contrary, if the Company gives a Suspension Notice pursuant to this Section 2.2 with respect to the
Resale Registration Statement, the Company shall extend the period during which the Resale Registration Statement shall be maintained
effective under this Agreement by the number of days during the period from the date of the giving of the Suspension Notice to
and including the date when the Holders shall have received the End of Suspension Notice and copies of the supplemented or amended
prospectus necessary to resume sales.

 

(f)       The
Company shall bear all Registration Expenses incurred by the Company in connection with the registration of the Registrable Securities
pursuant to this Agreement.

 

(g)       Notwithstanding
anything to the contrary contained in this Agreement, the Company shall not be required to include Registrable
Securities in the Resale Registration Statement unless the Holder owning the Registrable Securities to be registered on
the Resale Registration Statement, following reasonable advance written request by the Company, furnishes to the Company, at least
10 Business Days prior to the scheduled filing date of the Resale Registration Statement, an executed stockholder questionnaire
in the form attached hereto as Exhibit A.

 

    	 	5	 

     

    

 

2.3       Indemnification.

 

(a)       In
the event of the offer and sale of the Registrable Securities held by the Holders
under the Securities Act, the Company agrees to indemnify and hold harmless each Holder and its directors, officers, employees,
Affiliates and agents and each Person who controls such Holder within the meaning of the Securities Act or the Exchange Act (collectively,
the “Holder Indemnified Parties”) from and against any
losses, claims, damages or liabilities, joint or several, or any actions in respect thereof to which each Holder
Indemnified Party may become subject under the Securities Act or the Exchange Act, insofar as such losses, claims, damages, liabilities
or actions arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained
in the Resale Registration Statement or in any amendment thereof, in each case at the time such became effective under the Securities
Act, or in the preliminary prospectus or other information that is deemed, under Rule 159 promulgated under the Securities Act
to have been conveyed to purchasers of securities at the time of sale of such securities (“Disclosure Package”),
in the prospectus or in any amendment thereof or supplement thereto, or (ii) the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein (in the case of a Disclosure Package
or any prospectus, in the light of the circumstances under which they were made) not misleading, and shall reimburse, as incurred,
the Holder Indemnified Parties for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action in
respect thereof; provided, however, that the Company shall not be liable in any such case to the extent that such
loss, claim, damage or liability arises out of or is based upon any untrue statement or omission made in the Resale Registration
Statement, the Disclosure Package, any prospectus or in any amendment thereof or supplement thereto in reliance upon and in conformity
with written information pertaining to a Holder and furnished to
the Company by or on behalf of such Holder Indemnified Party specifically
for inclusion therein; provided further, however, that the Company shall not be liable in any such case to the extent that
such loss, claim, damage or liability arises out of or is based upon any untrue statement or alleged untrue statement or omission
or alleged omission made in the Disclosure Package, where (A) such statement or omission had been eliminated or remedied in
any subsequently filed amended prospectus or prospectus supplement (the Disclosure Package, together with such updated documents,
the “Updated Disclosure Package”), the filing of which such Holder had been notified in accordance with
the terms of this Agreement, (B) such Updated Disclosure Package was available at the time such Holder
sold Registrable Securities under the Resale Registration Statement, (C) such Updated Disclosure Package was not furnished
by such Holder to the Entity asserting the loss, liability, claim, damage or liability, or an underwriter involved in the distribution
of such Registrable Securities, at or prior to the time such furnishing is required by the Securities Act, and (D) the Updated
Disclosure Package would have cured the defect giving rise to such loss, liability, claim, damage or action; and provided further,
however, that this indemnity agreement will be in addition to any liability that the Company may otherwise have to such
Holder Indemnified Party. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of any Holder Indemnified Parties and shall survive the transfer
of the Registrable Securities by any Holder.

 

    	 	6	 

     

    

 

(b)       As
a condition to including any Registrable Securities to be offered by a Holder
in any registration statement filed pursuant to this Agreement, such Holder agrees to severally and not jointly indemnify and hold
harmless the Company, each of its directors, each of its officers who signs the Resale Registration Statement, as well as any officers,
employees, Affiliates and agents of the Company, and each Person, if any, who controls the Company within the meaning of the Securities
Act or the Exchange Act (a “Company Indemnified Party”) from and against any losses, claims, damages
or liabilities or any actions in respect thereof, to which a Company Indemnified Party may become subject under the Securities
Act or the Exchange Act, insofar as such losses, claims, damages, liabilities or actions arise out of or are based upon (i) any
untrue statement or alleged untrue statement of a material fact contained in the Resale Registration Statement or in any amendment
thereof, in each case at the time such became effective under the Securities Act, or in any Disclosure Package, prospectus or in
any amendment thereof or supplement thereto, or (ii) the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein (in the case of the Disclosure Package or any prospectus, in the
light of the circumstances under which they were made) not misleading, but in each case only to the extent that the untrue statement
or omission or alleged untrue statement or omission was made in reliance upon and in conformity with written information pertaining
to such Holder and furnished to the Company by or on behalf of such Holder specifically for inclusion therein; and, subject to
the limitation immediately preceding this clause, shall reimburse, as incurred, the Company Indemnified Parties for any legal or
other expenses reasonably incurred by them in connection with investigating or defending any loss, claim, damage, liability or
action in respect thereof. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of such Holder, or any such director, officer, employees, Affiliates and agents and shall survive the transfer of such Registrable
Securities by such Holder, and such Holder shall reimburse the Company, and each such director, officer, employees, Affiliates
and agents for any legal or other expenses reasonably incurred by them in connection with investigating, defending, or settling
and such loss, claim, damage, liability, action, or proceeding; provided, however, that the indemnity amount contained in
this Section 2.3(b) shall in no event exceed the gross proceeds from the offering received by such Holder. Such indemnity shall
remain in full force and effect, regardless of any investigation made by or on behalf of the Company or any such director, officer,
employees, Affiliates and agents and shall survive the transfer by a Holder of such Registrable Securities.

 

    	 	7	 

     

    

 

(c)       Promptly
after receipt by a Holder Indemnified Party or a Company Indemnified Party (each, an “Indemnified Party”)
of notice of the commencement of any action or proceeding (including a governmental investigation), such Indemnified Party will,
if a claim in respect thereof is to be made against the indemnifying party under this Section 2.3, notify the indemnifying party
of the commencement thereof; but the omission to so notify the indemnifying party will not relieve the indemnifying party from
liability under Sections 2.3(a) or 2.3(b)  unless and to the extent it did not otherwise learn of such action and the indemnifying
party has been materially prejudiced by such failure. In case any such action is brought against any Indemnified Party, and it
notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and,
to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with
counsel reasonably satisfactory to such Indemnified Party (who shall not, except with the consent of the Indemnified Party, be
counsel to the indemnifying party), and after notice from the indemnifying party to such Indemnified Party of its election so to
assume the defense thereof the indemnifying party will not be liable to such Indemnified Party under this Section 2.3 for any legal
or other expenses, other than reasonable costs of investigation, subsequently incurred by such Indemnified Party in connection
with the defense thereof; provided, however, if such Indemnified Party shall have been advised by counsel that there
are one or more defenses available to it that are in conflict with those available to the indemnifying party (in which case the
indemnifying party shall not have the right to direct the defense of such action on behalf of the Indemnified Party), the reasonable
fees and expenses of such Indemnified Party’s counsel shall be borne by the indemnifying party. In no event shall the indemnifying
party be liable for the fees and expenses of more than one counsel (together with appropriate local counsel) at any time for any
Indemnified Party in connection with any one action or separate but substantially similar or related actions arising in the same
jurisdiction out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent
of the Indemnified Party (not to be unreasonably withheld or delayed), effect any settlement of any pending or threatened action
in respect of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such
Indemnified Party unless such settlement (i) includes an unconditional release of such Indemnified Party from all liability
on any claims that are the subject matter of such action and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any Indemnified Party. If the indemnification provided for in this Section 2.3
is unavailable or insufficient to hold harmless an Indemnified Party under Sections 2.3(a) or 2.3(b), then each indemnifying party
shall contribute to the amount paid or payable by such Indemnified Party as a result of the losses, claims, damages or liabilities
(or actions in respect thereof) referred to in Sections 2.3(a) or 2.3(b) in such proportion as is appropriate to reflect the relative
fault of the indemnifying party or parties on the one hand and the Indemnified Party on the other in connection with the statements
or omissions that resulted in such losses, claims, damages or liabilities (or actions in respect thereof) as well as any other
relevant equitable considerations. The relative fault of the parties shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the Company on the one hand or a Holder or Holder Indemnified Party, as the case may be, on the other,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The amount paid by an Indemnified Party as a result of the losses, claims, damages or liabilities referred to in the
first sentence of this Section 2.3 shall be deemed to include any legal or other expenses reasonably incurred by such Indemnified
Party in connection with investigating or defending any action or claim that is the subject of this Section 2.3(c). The parties
agree that it would not be just and equitable if contributions were determined by pro rata allocation (even if a Holder
was treated as one Entity for such purpose) or any other method of allocation that does not take account of the equitable considerations
referred to above. Notwithstanding any other provision of this Section 2.3(c), no Holder shall be required to contribute any amount
in excess of the amount by which the net proceeds received by such Holder from the sale of the Registrable Securities pursuant
to the Resale Registration Statement exceeds the amount of damages that such Holder has otherwise been required to pay by reason
of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation.

 

    	 	8	 

     

    

 

(d)       The
agreements contained in this Section 2.3 shall survive the sale of the Registrable Securities pursuant to the Resale Registration
Statement and shall remain in full force and effect, regardless of any termination or cancellation of this Agreement or any investigation
made by or on behalf of any Indemnified Party.

 

Article
III.

Transfer Restrictions

 

3.1       Transfer
Restrictions. Each Holder acknowledges and agrees to the that the following legend shall be imprinted on any certificate or
book-entry security entitlement evidencing any of the Registrable Securities:

 

THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF
TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE
EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

This legend shall be
removed by the Company from any certificate or book-entry security entitlement evidencing the Registrable Securities upon delivery
by the holder thereof to the Company of a written request to that effect if at the time of such written request (i) a registration
statement under the Securities Act is at that time in effect with respect to the legended security, or (ii) the legended security
can be transferred in a transaction in compliance with Rule 144 under the Securities Act, and, in the case of (ii), upon the request
and in the reasonable discretion of the Company’s transfer agent, the holder of such Registrable Securities executes and
delivers a representation letter that includes customary representations regarding the holding requirements and whether such holder
is an “affiliate” for purposes of Rule 144 under the Securities Act. The Company represents and warrants to the Purchasers
that the Company is not currently a shell company (as defined in Rule 405 promulgated under the Securities Act).

 

Article
IV.

Miscellaneous.

 

4.1       Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

    	 	9	 

     

    

 

4.2       Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally; (b) upon receipt, when sent
by e-mail (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
or (c) one calendar day (excluding Saturdays, Sundays, and national banking holidays in the United States) after deposit with an
overnight courier service, in each case properly addressed to the party to receive the same.

 

The addresses
and e-mail addresses for such communications shall be:

 

If to the Company:

 

Sorrento Therapeutics Inc.

4955 Directors Place

San Diego, California 92121

E-mail: hji@sorrentotherapeutics.com

Attn: Henry Ji, Ph.D.

 

With a copy (which shall not constitute
notice) to:

 

Paul Hastings LLP

4747 Executive Drive, 12th Floor

San Diego, CA 92121

E-mail: jeffhartlin@paulhastings.com

Attn: Jeffrey Hartlin, Esq.

 

If to a Purchaser: To the address set forth
opposite such Purchaser’s name on Schedule A hereto;

 

or to such other address
and/or e-mail address and/or to the attention of such other person as the recipient party has specified by written notice given
to each other party at least five (5) days prior to the effectiveness of such change.

 

4.3       Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

4.4       Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that
a .pdf or other form of electronic signature shall be considered due execution and shall be binding upon the signatory thereto
with the same force and effect as if the signature were an original, not a .pdf or other form of electronic signature.

 

    	 	10	 

     

    

 

4.5       Governing
Law; Arbitration; Venue. This Agreement shall be construed under the laws of the State of California, without regard to principles
of conflicts of law or choice of law that would permit or require the application of the laws of another jurisdiction. The Company
and each of the Purchasers hereby agrees that all actions or proceedings arising directly or indirectly from or in connection with
this Agreement shall be litigated only in the Superior Court of the State of California or the United States District Court for
the Southern District of California located in San Diego County, California. The Company and each of the Purchasers consent to
the exclusive jurisdiction and venue of the foregoing courts and consents that any process or notice of motion or other application
to either of said courts or a judge thereof may be served inside or outside the State of California or the Southern District of
California by generally recognized overnight courier or certified or registered mail, return receipt requested, directed to such
party at its or his address set forth below (and service so made shall be deemed “personal service”) or by personal
service or in such other manner as may be permissible under the rules of said courts. THE COMPANY AND EACH OF THE PURCHASERS HEREBY
WAIVES ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS AGREEMENT.

 

4.6       Assignment
and Successors. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns, including any purchasers of the Notes and/or the Warrants.

 

4.7       Entire
Agreement; Amendments. This Agreement supersedes all other prior oral or written agreements between the Purchasers, the Company,
their Affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except
as specifically set forth herein or therein, none of the Company or any of the Purchasers makes any representation, warranty, covenant
or undertaking with respect to such matters. No provision of this Agreement may be amended, waived or modified other than by an
instrument in writing signed by the Company and: (a) prior to the Closing, the Purchasers purchasing at least a majority of the
aggregate principal amount of the Notes, as set forth on Schedule A hereto,
or (b) after the Closing, the Purchasers holding at least a majority of the aggregate principal amount of the then-outstanding
Notes. Any such amendment, waiver or modification effected in accordance with this Section 4.7 shall be binding upon all
Purchasers and each transferee of the Notes (or the Note Shares) or the Warrants (or the Warrant Shares), each future holder of
all such securities and the Company.

 

4.8       Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

4.9       Termination.
This Agreement shall terminate on the date when there are no longer any remaining Registrable Securities or upon the dissolution,
liquidation or winding up of the Company; provided that Section 2.3 of this Agreement shall survive such termination.

 

4.10       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

    	 	11	 

     

    

 

4.11       Language;
Currency. This Agreement has been prepared in the English language and the English language shall control its interpretation.
In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications
between the parties regarding this Agreement, shall be in the English language. All references to “$” contained in
this Agreement shall refer to United States Dollars unless otherwise stated.

 

[The
remainder of this page intentionally left blank]

 

 

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	THE COMPANY:
	 	 	 	 
	 	Sorrento Therapeutics, Inc.,
	 	a Delaware corporation
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Henry Ji, Ph.D.
	 	 	Name:	Henry Ji, Ph.D.
	 	 	Title:	President and Chief Executive Officer

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	PURCHASERS:
	 	 	 	 
	 	ASIA PACIFIC MEDTECH (BVI) LIMITED
	 	 	 	 
	 	By:	/s/ GU NANA
	 	 	Name:	GU NANA
	 	 	Title:	Director

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

  

 

	 	PURCHASERS:
	 	 	 	 
	 	Famous Sino Limited
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Guangze WU
	 	 	Name:	Guangze WU
	 	 	Title:	Director

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	PURCHASERS:
	 	 	 	 
	 	China In Shine Investment Limited
	 	 	 	 
	 	 	 	 
	 	By:	/s/ CHIT FUNG
	 	 	Name:	CHIT FUNG
	 	 	Title:	Director

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	PURCHASERS:
	 	 	 	 
	 	Himark Group (Holdings) Company Limited
	 	 	 	 
	 	 	 	 
	 	By:	/s/ O Na
	 	 	Name:	O Na
	 	 	Title:	Director

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	PURCHASERS:
	 	 	 	 
	 	SUCCESS INDICATOR INVESTMENTS LIMITED
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Kang LI
	 	 	Name:	Kang LI
	 	 	Title:	Director

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Registration Rights Agreement as of the date first written above.

 

 

	 	PURCHASERS:
	 	 	 	 
	 	PIPELINE VENTURES, LLC
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Patrick Lin
	 	 	Name:	Patrick Lin
	 	 	Title:	Partner

 

 

    	 	[Signature Page to Registration Rights Agreement]
	 

     

    

 

Schedule
A

 

Purchasers

 

	Purchaser	Contact Information for Notices	Principal Amount of Note Purchased	Shares Issuable Upon Conversion of Notes	Shares Issuable Upon Exercise of Warrants	Total Registrable Securities
	Asia Pacific MedTech (BVI) Limited	c/o Offshore Incorporations Limited, P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands	$10,000,000	1,426,024	713,012	2,139,036
	Famous Sino Limited	Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands	$5,610,000	800,000	400,000	1,200,000
	China In Shine Investment Limited	Flat F, 12/F, Tower 5, Harbour Green, 8 Sham Mong Road, Tai Kok Tsui, Kowloon, Hong Kong	$7,713,750	1,100,000	550,000	1,650,000
	Himark Group (Holdings) Company Limited	Flat C, 7/F, One Island Place, 51 Tanner Road, North Point, Hong Kong	$7,012,500	1,000,000	500,000	1,500,000
	Success Indicator Investments Limited	P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands	$7,012,500	1,000,000	500,000	1,500,000
	Pipeline Ventures, LLC	
        Pipeline Ventures, LLC

        c/o Patrick Lin

        21 “C” Orinda Way #138

        Orinda, CA 94563
	$500,000	71,301	35,650	106,951
	TOTAL	$37,848,750.00	5,397,325	2,698,662	8,095,987

 

    	 	Schedule A	 

     

    

  

Exhibit
A

 

Form
of Selling Stockholder Questionnaire

 

SORRENTO THERAPEUTICS, INC.

SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE

 

The undersigned holder
of convertible promissory notes and warrants issued by Sorrento Therapeutics, Inc. (the “Company”) understands
that the Company intends to file with the Securities and Exchange Commission a registration statement on Form S-3 (the “Resale
Registration Statement”) for the registration and the resale under Rule 415 of the Securities Act of 1933, as amended
(the “Securities Act”), of the Registrable Securities in accordance with the terms of the Registration
Rights Agreement, dated June 13, 2018, by and among the Company and the several signatories thereto (the “Registration
Rights Agreement”). All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in
the Registration Rights Agreement.

 

In order to sell or
otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable Securities
generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented,
the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities (including pursuant
to Rule 172 under the Securities Act) and be bound by the provisions of the Registration Rights Agreement (including certain indemnification
provisions, as described therein). Holders must complete and deliver this notice and questionnaire (“Notice and Questionnaire”)
in order to be named as selling stockholders in the Prospectus. Certain legal consequences arise from being named as a selling
stockholder in the Resale Registration Statement and the Prospectus. Holders of Registrable Securities are advised to consult their
own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the Resale Registration
Statement and the Prospectus.

 

NOTICE

 

The undersigned holder
(the “Selling Stockholder”) of Registrable Securities hereby gives notice to the Company of its intention
to sell or otherwise dispose of Registrable Securities owned by it and listed below in Part 3(b) pursuant to the Resale Registration
Statement. The undersigned, by signing and returning this Notice and Questionnaire, understands and agrees that it will be bound
by the terms and conditions of this Notice and Questionnaire and the Registration Rights Agreement.

 

The undersigned hereby
provides the following information to the Company and represents and warrants that such information is materially accurate and
complete:

 

    	 	A-1	 

     

    

 

QUESTIONNAIRE

 

PART 1. Name:

 

		1.1	Full legal name of the Selling Stockholder:
	 	 	 
	 	 	 

 

		1.2	Full legal name of the registered holder (if not the same as Part 1(a) above) through which the
Registrable Securities listed in Part(3) below are held:
	 	 	 
	 	 	 

 

		1.3	Full legal name of any natural control person (which means a natural person who directly or indirectly
alone or with others has power to vote or dispose of the Registrable Securities listed in Part (3) below):
	 	 	 
	 	 	 

  

PART II. Notices to Selling Stockholder:

 

		(a)	Address:
	 	 	 
	 	 	 

 

		(b)	Telephone:
	 	 	 
	 	 	 

 

		(c)	Fax:
	 	 	 
	 	 	 

 

		(d)	Contact person:
	 	 	 
	 	 	 

 

		(e)	E-mail address of contact person:
	 	 	 
	 	 	 

 

    	 	A-2	 

     

    

 

PART III. Beneficial Ownership of Registrable
Securities:

 

		(a)	Type and number of Registrable Securities beneficially
owned:
	 	 	 
	 	 	 
	 	 	 
	 	 	 

  

		(b)	Number of shares of Common Stock to be registered for resale pursuant to this Notice and Questionnaire:
	 	 	 
	 	 	 
	 	 	 
	 	 	 

  

PART IV. Broker-Dealer Status:

 

		(a)	Are you a broker-dealer?

 

	 	Yes  ̈	No  ̈

 

		(b)	If you answered “yes” to Part 4(a) above, did you receive your Registrable Securities
as compensation for investment banking services provided to the Company?

 

	 	Yes  ̈	No  ̈

 

	 	Note: If you answered “no”, the SEC’s staff has indicated that you should be identified as an underwriter in the Resale Registration Statement.

 

		(c)	Are you an affiliate of a broker-dealer?

 

	 	Yes  ̈	No  ̈

 

	 	If you answered “yes”, provide a narrative explanation below:

 

	 	 
	 	 
	 	 

 

		(d)	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities
in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

 

	 	Yes  ̈	No  ̈

 

	 	Note: If you answered “no”, the SEC’s staff has indicated that you should be identified as an underwriter in the Resale Registration Statement.

 

    	 	A-3	 

     

    

 

PART
V. Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder:

 

Except as set forth
below in this Part 5, the undersigned is not the beneficial or registered owner of any securities of the Company, other than the
Registrable Securities listed above in Part 3.

 

Type and amount of
other securities beneficially owned:

 

	 	 
	 	 
	 	 

 

PART VI. Relationships with the Company:

 

		(a)	Have you or any of your affiliates, officers, directors or principal equity holders (owners of
5% or more of the equity securities of the undersigned) held any position or office or have you had any other material relationship
with the Company (or its predecessors or affiliates) within the past three years?

 

	 	Yes  ̈	No  ̈

 

		(b)	If your response to Part 6(a) above is “yes”, please state the nature and duration
of your relationship with the Company:

 

	 	 
	 	 
	 	 

  

PART VII. Plan of Distribution:

 

The undersigned has
reviewed the form of Plan of Distribution attached as Annex A hereto, and hereby confirms that, except as set forth below,
the information contained therein regarding the undersigned and its plan of distribution is correct and complete.

 

State any exceptions
here:

 

	 	 
	 	 
	 	 

 

 

    	 	A-4	 

     

    

  

The undersigned agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder shall be delivered
as set forth in the Registration Rights Agreement. In the absence of any such notification, the Company shall be entitled to continue
to rely on the accuracy of the information in this Notice and Questionnaire.

 

By signing below, the
undersigned consents to the disclosure of the information contained herein in its answers to Parts 1 through 7 above and the inclusion
of such information in the Resale Registration Statement and the Prospectus. The undersigned understands that such information
will be relied upon by the Company in connection with the preparation or amendment of any such Resale Registration Statement and
Prospectus.

 

By signing below, the
undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the
Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of Registrable
Securities pursuant to the Resale Registration Statement. The undersigned also acknowledges that it understands that the answers
to this Notice and Questionnaire are furnished for use in connection with registration statements filed pursuant to the Registration
Rights Agreement and any amendments or supplements thereto filed with the SEC pursuant to the Securities Act.

 

The undersigned confirms
that, to the best of his/her knowledge and belief, the foregoing answers to this Notice and Questionnaire are correct.

 

IN WITNESS WHEREOF,
the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
or by its duly authorized agent.

 

Dated: _____________

 

	 	Selling Stockholder:
	 	 
	 	 
	 	 
	 	 
	 	Name of Entity or Individual

 

 

	 	By:	 
	 	Name:	 
	 	Title:	 

 

 

    	 	A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]